NRX Pharmaceuticals, Inc. Research and Development Expense
NRX Pharmaceuticals, Inc. (NRXP) reported Research and Development Expense of $2.12 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-14
- NRX Pharmaceuticals, Inc. research and development expense for the quarter ending 2026-06-30 was $2.12M, a 114.39% increase year-over-year.
- NRX Pharmaceuticals, Inc. research and development expense for the quarter ending 2026-03-31 was $1.31M, a 62.81% increase year-over-year.
- NRX Pharmaceuticals, Inc. research and development expense for the quarter ending 2025-12-31 was $558.00K, a 46.14% decline year-over-year.
- NRX Pharmaceuticals, Inc. research and development expense for the quarter ending 2025-09-30 was $1.43M, a 133.88% increase year-over-year.
- NRX Pharmaceuticals, Inc. research and development expense for fiscal 2025 was $3.78M, a 39.07% decline from fiscal 2024.
- NRX Pharmaceuticals, Inc. research and development expense for fiscal 2024 was $6.20M, a 53.64% decline from fiscal 2023.
- NRX Pharmaceuticals, Inc. research and development expense for fiscal 2023 was $13.37M, a 21.47% decline from fiscal 2022.
- NRX Pharmaceuticals, Inc. research and development expense for fiscal 2022 was $17.03M, a 15.95% decline from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 3 month as first filed | Research and Development Expense 6 month | Research and Development Expense 6 month as first filed | Research and Development Expense 9 month | Research and Development Expense 9 month as first filed | Research and Development Expense 12 month |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $2.12M 10-Q · filed 2026-08-14 | $3.42M 10-Q · filed 2026-08-14 | $3.98M derived: sum of 3 quarters · filed 2026-08-14 | $5.41M derived: sum of 4 quarters · filed 2026-08-14 | |||
| 2026-03-31 | $1.31M 10-Q · filed 2026-05-15 | $1.87M derived: sum of 2 quarters · filed 2026-05-15 | $3.30M derived: sum of 3 quarters · filed 2026-05-15 | $4.28M derived: sum of 4 quarters · filed 2026-08-14 | |||
| 2025-12-31 | $558.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | $1.99M derived: sum of 2 quarters · filed 2026-03-23 | $2.97M derived: sum of 3 quarters · filed 2026-08-14 | $3.78M 10-K · filed 2026-03-23 | |||
| 2025-09-30 | $1.43M 10-Q · filed 2025-11-14 | $2.42M derived: sum of 2 quarters · filed 2026-08-14 | $3.22M 10-Q · filed 2025-11-14 | $4.26M derived: sum of 4 quarters · filed 2026-08-14 | |||
| 2025-06-30 | $987.00K 10-Q · filed 2026-08-14 | $1.79M 10-Q · filed 2026-08-14 | $2.83M derived: sum of 3 quarters · filed 2026-08-14 | $3.44M derived: sum of 4 quarters · filed 2026-08-14 | |||
| 2025-03-31 | $804.00K 10-Q · filed 2026-05-15 | $1.84M derived: sum of 2 quarters · filed 2026-05-15 | $2.45M derived: sum of 3 quarters · filed 2026-05-15 | $5.25M derived: sum of 4 quarters · filed 2026-05-15 | |||
| 2024-12-31 | $1.04M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | $1.65M derived: sum of 2 quarters · filed 2026-03-23 | $4.45M derived: sum of 3 quarters · filed 2026-03-23 | $6.20M 10-K · filed 2026-03-23 | |||
| 2024-09-30 | $611.00K 10-Q · filed 2025-11-14 | $3.42M derived: sum of 2 quarters · filed 2025-11-14 | $5.16M 10-Q · filed 2025-11-14 | $7.70M derived: sum of 4 quarters · filed 2025-11-14 | |||
| 2024-06-30 | $2.80M 10-Q · filed 2025-08-18 | $4.55M 10-Q · filed 2025-08-18 | $7.09M derived: sum of 3 quarters · filed 2025-08-18 | $10.40M derived: sum of 4 quarters · filed 2025-08-18 | |||
| 2024-03-31 | $1.75M 10-Q · filed 2025-05-15 | $4.28M derived: sum of 2 quarters · filed 2025-05-15 | $7.60M derived: sum of 3 quarters · filed 2025-05-15 | $11.47M derived: sum of 4 quarters · filed 2025-05-15 | |||
| 2023-12-31 | $2.53M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-14 | $5.85M derived: sum of 2 quarters · filed 2025-03-14 | $9.72M derived: sum of 3 quarters · filed 2025-03-14 | $13.37M 10-K · filed 2025-03-14 | |||
| 2023-09-30 | $3.31M 10-Q · filed 2024-11-14 | $7.19M derived: sum of 2 quarters · filed 2024-11-14 | $10.84M 10-Q · filed 2024-11-14 | $12.45M derived: sum of 4 quarters · filed 2025-05-15 | |||
| 2023-06-30 | $3.87M 10-Q · filed 2024-08-14 | $7.52M 10-Q · filed 2024-08-14 | $9.13M derived: sum of 3 quarters · filed 2025-05-15 | $13.26M derived: sum of 4 quarters · filed 2025-05-15 | |||
| 2023-03-31 | $804.00K 10-Q · filed 2025-05-15 | $3.65M 10-Q · filed 2023-05-15 | $5.26M derived: sum of 2 quarters · filed 2025-05-15 | $9.39M derived: sum of 3 quarters · filed 2025-05-15 | $12.35M derived: sum of 4 quarters · filed 2025-05-15 | ||
| 2022-12-31 | $4.46M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29 | $8.59M derived: sum of 2 quarters · filed 2024-03-29 | $11.54M derived: sum of 3 quarters · filed 2024-03-29 | $17.03M 10-K · filed 2024-03-29 | |||
| 2022-09-30 | $4.13M 10-Q · filed 2023-11-14 | $7.09M derived: sum of 2 quarters · filed 2023-11-14 | $12.57M 10-Q · filed 2023-11-14 | $18.98M derived: sum of 4 quarters · filed 2023-11-14 | |||
| 2022-06-30 | $2.96M 10-Q · filed 2023-08-14 | $8.44M 10-Q · filed 2023-08-14 | $14.85M derived: sum of 3 quarters · filed 2023-08-14 | $21.13M derived: sum of 4 quarters · filed 2023-08-14 | |||
| 2022-03-31 | $5.48M 10-Q · filed 2023-05-15 | $11.90M derived: sum of 2 quarters · filed 2023-05-15 | $18.17M derived: sum of 3 quarters · filed 2023-05-15 | $22.83M derived: sum of 4 quarters · filed 2023-05-15 | |||
| 2021-12-31 | $6.41M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | $12.69M derived: sum of 2 quarters · filed 2023-03-31 | $17.35M derived: sum of 3 quarters · filed 2023-03-31 | $20.26M 10-K · filed 2023-03-31 | |||
| 2021-09-30 | $6.28M 10-Q · filed 2022-11-14 | $6.28M 10-Q · filed 2021-11-15 | $10.94M derived: sum of 2 quarters · filed 2022-11-14 | $13.84M 10-Q · filed 2022-11-14 | $13.84M 10-Q · filed 2021-11-15 | $18.14M derived: sum of 4 quarters · filed 2022-11-14 | |
| 2021-06-30 | $4.66M 10-Q · filed 2022-08-15 | $4.66M 10-Q · filed 2021-08-16 | $7.57M 10-Q · filed 2022-08-15 | $7.57M 10-Q · filed 2021-08-16 | $11.87M derived: sum of 3 quarters · filed 2022-08-15 | $16.20M derived: sum of 4 quarters · filed 2022-08-15 | |
| 2021-03-31 | $2.91M 10-Q · filed 2022-05-16 | $7.21M derived: sum of 2 quarters · filed 2022-05-16 | $11.54M derived: sum of 3 quarters · filed 2022-08-12 | $12.93M derived: sum of 4 quarters · filed 2022-08-12 | |||
| 2020-12-31 | $4.30M derived: 10-K 12 month − 10-Q/A 9 month · filed 2022-03-31 | $8.63M derived: sum of 2 quarters · filed 2022-08-12 | $10.02M derived: sum of 3 quarters · filed 2022-08-12 | $10.63M 10-K · filed 2022-03-31 | |||
| 2020-09-30 | $4.33M 10-Q/A · filed 2022-08-12 | $5.72M derived: sum of 2 quarters · filed 2022-08-12 | $6.33M 10-Q/A · filed 2022-08-12 | ||||
| 2020-06-30 | $1.39M 10-Q/A · filed 2022-08-12 | $1.99M 10-Q/A · filed 2022-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |
| INOVIO PHARMACEUTICALS, INC. (INO) | United States | $0.125B | -1.35 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| Aardvark Therapeutics, Inc. (AARD) | United States | $0.121B | -1.80 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |